Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L) Clinical Trial
Official title:
Fresh Pomegranate Juice Decreases Fasting Serum Erythropoietin in Patients With Type 2 Diabetes
Fresh pomegranate juice at 1.5 mL/kg of body weight was administered by recruited healthy
individuals and patients with type 2 diabetes of fasting serum glucose between 7.1 and 15.8
mmol/L after approximately 12 hours fasting. Blood samples were collected in plain tubes
before (-5 minutes) and at 1 and 3 hours after drinking pomegranate juice. Blood samples were
centrifuged and serum was collected and stored for glucose and hormonal analysis. Patients
were recruited from those of earlier stages of type 2 diabetes, and many of them already
drink pomegranate juice as of its benefits for their health).
The exclusion criteria included subjects with renal or hepatic disease, pregnancy, treatment
with insulin, and hormone therapies. Participants who had either smoked cigarettes or taken
antioxidant supplements, lipid-lowering drugs, and oral hypoglycemic agents, such as
metformin (glucophage) or sulfonylureas, within the preceding 12 hours were also excluded.
The study was explained to all of the recruited subjects by the clinical researchers, and
written informed consent was obtained prior to enrollment. Approval for the study was
provided by the IRB Committee at Jordan University of Science and Technology (Irbid, Jordan).
n/a